Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Recurrent High Grade Serous Ovarian Cancer Management

Mathieu Luyckx  1   2 , Jean-Luc Squifflet  1 , Annika M. Bruger  2 , Jean-François Baurain  1
Shashikant Lele  1
, editors.
In: Ovarian Cancer [Internet]. Brisbane (AU): Exon Publications; 2022 Sep 8. Chapter 6.
Affiliations
Free Books & Documents
Review

Recurrent High Grade Serous Ovarian Cancer Management

Mathieu Luyckx et al.
Free Books & Documents

Excerpt

Despite an aggressive treatment strategy for high grade serous ovarian cancer (HGSOC) that incorporates cytoreduction, platinum compounds, anti-angiogenic agents, and poly (ADP-ribose) polymerase (PARP) inhibitors, most patients, especially those who are with stage III-IV HGSOC, will relapse. The management of recurrent HGSOC is a challenging issue faced by gyneco-oncologists and medical oncologists in clinical practice. This chapter provides an overview of the current optimal management of recurrent HGSOC. First, recurrence is classified based on the time of onset. This is followed by a discussion on the place of surgery within the treatment strategy. Finally, the role of systemic treatments (chemotherapy, targeted agents, and immunotherapy) in the management of HGSOC are presented.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflict of interest with respect to research, authorship and/or publication of this chapter.

References

    1. International Collaborative Ovarian Neoplasm G Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505–15. https://doi.org/10.1016/S0140-6736(02)09738-6 . - DOI - PubMed
    1. DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. J Clin Oncol. 2020;38(30):3528–37. https://doi.org/10.1200/JCO.20.00799 . - DOI - PMC - PubMed
    1. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236–43. https://doi.org/10.1016/S1470-2045(12)70567-3 . - DOI - PMC - PubMed
    1. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962 . - DOI - PubMed
    1. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, et al. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018;4(11):1519–26. https://doi.org/10.1001/jamaoncol.2018.2761 . - DOI - PMC - PubMed

LinkOut - more resources